ClinicalTrials.gg
RecruitingNCT07402551Updated Sep 8, 2026

Phase II Study of RC1416 Injection in COPD

A Phase 2 interventional study of RC1416 and RC1416 Placebo in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), sponsored by Nanjing RegeneCore Biotech Co., Ltd.. Recruiting at 46 sites in China. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Nanjing RegeneCore Biotech Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 110 open to participants now, 127 under way, 16 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Planned enrollment
138th of 288
180 · median 155
Started
2026
with 35 others
Phase 2
33 of 406
13 open now
Primary completion
2028-05
later than 94 of 126 live
Registered
368th of 406
by date

Among the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 138th largest by planned enrollment of the 288 interventional ones that give a count, is one of 36 that started in 2026, is one of 33 in phase 2, reaches primary completion later than 94 of the 126 other live ones, and was the 368th registered.

Pulmonary Disease, Chronic Obstructive

5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

110 of the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

104 more — sign in →

All 110 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of RC1416 injection in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Read the detailed description

Each participant will receive the study treatment once every two weeks for a total treatment duration of 52 weeks. The study aims to evaluate the annualized rate of moderate or severe COPD exacerbations (AECOPD) and the change in FEV1 from baseline over the 52-week treatment period. The changes in FeNO, total IgE, eosinophil count, and TARC levels from baseline will be evaluated.

03

Conditions studied

  • Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 40 to 85 years (inclusive) at the time of signing the form, regardless of gender.
  • (BMI) ≥ 16 kg/m².
  • Meets the diagnostic criteria for (COPD), and has medical records or relevant documentation indicating a history of COPD for ≥ 12 months at screening.
  • Post-bronchodilator ratio of (FEV1) to forced vital capacity (FVC) \< 0.7, and post-bronchodilator FEV1 ≥ 30% and \< 80% of the predicted value at screening.
  • A current smoker or former smoker with a smoking history of ≥ 10 pack-years, or a history of exposure to other risk factors.
  • A score of ≥ 2 on the modified Medical Research Council (mMRC) dyspnea scale at screening.
  • Medical records or relevant documentation showing ≥ 2 moderate COPD. exacerbations (AECOPD) or ≥ 1 severe AECOPD within the 12 months prior to screening.
  • Medical records or relevant documentation showing receipt of background triple therapy (ICS + LABA + LAMA) for ≥ 3 months prior to randomization.
  • A blood eosinophil count ≥ 150/mm³ (0.15×10⁹/L) at screening.

Exclusion criteria

Exclusion Criteria:

  • A current diagnosis of asthma or a history of asthma.
  • Presence of other significant pulmonary diseases except as judged by the Investigator.
  • History of .
  • A history of diseases , or treatment with biologics or systemic for inflammatory diseases within 8 weeks or 5 half-lives (whichever is longer) prior to signing the form.
  • Presence of recurrent, chronic, or other active infections at screening.
  • Currently receiving or planning to start long-term oxygen therapy or mechanical ventilation during the study period.
  • Diagnosis of α1-antitrypsin deficiency.
  • Active , active , positive (HIV) antibody, or positive Treponema pallidum antibody (TP-Ab).
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    RC1416 Injection

    Drug: RC1416

  • Placebo comparator
    Placebo Control

    Drug: RC1416 Placebo

Interventions

  • DrugRC1416

    There are two doses in this part. Each subjects will receive the drug by subcutaneous injection.

  • DrugRC1416 Placebo

    Each subjects will receive the placebo by subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. moderate or severe COPD exacerbations (AECOPD) and forced expiratory volume in 1 Second (FEV1)

    Evaluate the annualized rate of AECOPD and the change in FEV1 from baseline

    Time frame: During 52 weeks

Secondary outcomes

  1. The safety and tolerability

    Adverse events, laboratory tests, vital signs, 12-lead electrocardiogram (ECG), and physical examinations.

    Time frame: During 52 weeks

  2. pharmacokinetic

    Css, DF, Tmax.

    Time frame: During 52 weeks

  3. immunogenicity

    ADA positivity rate and titer, and NAb positivity rate.

    Time frame: During 52 weeks

  4. biomarkers predictive of the efficacy

    FeNO, total IgE, eosinophil count, and TARC levels.

    Time frame: During 52 weeks

07

Study locations

42 of 46 sites recruiting
  • Anhui Provincial Chest Hospital
    Hefei, Anhui 230031, China
    Recruiting
    • Haohui Fang · Contact
  • Wan Bei General Hospital of Wanbei Coal power Group
    Suzhou, Anhui 234000, China
    Recruiting
    • Hui Jiang · Contact
  • Yongchuan Hospital Affiliated to Chongqing Medical University
    Chongqing, Chongqing Municipality 402160, China
    Recruiting
  • The Affiliated Bishan Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 402760, China
    Recruiting
    • Rui Han · Contact
  • Zhongshan Hospital Xiamen University
    Xiamen, Fujian 361004, China
    Recruiting
    • Yanping Du · Contact
  • The first affiliated hospital of guangzhou medical university
    Guangzhou, Guangdong 510000, China
    Recruiting
    • Nanshan Zhong · Contact
  • The First Affiliated Hospital of Jinan University
    Guangzhou, Guangdong 510000, China
    Recruiting
    • Shenming Liu · Contact
  • The first affiliated hospital of guangzhou medical university
    Guangzhou, Guangdong, China
    Recruiting
    • Yuming Zhou · Contact
  • Huizhou Third People's Hospital
    Huizhou, Guangdong 516002, China
    Recruiting
    • Feng Wu · Contact
  • Jiangmen Central Hospital
    Jiangmen, Guangdong 529000, China
    Recruiting
    • Yanming Huang · Contact
  • Guangzhou Medical University Affiliated Qingyuan Hospital (Qingyuan People's Hospital)
    Qingyuan, Guangdong 511518, China
    Recruiting
    • Dongbo Tian · Contact
  • The First Affiliated Hospital of guangxi Medical University
    Nanning, Guangxi 530021, China
    Recruiting
    • Zhiyi He · Contact
  • The First People's Hospital of Yulin
    Yulin, Guangxi 537000, China
    Recruiting
    • Linling Zhu · Contact
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou 563000, China
    Recruiting
    • Yuanbo Lan · Contact
  • Anyang People's Hospital
    Anyang, Henan 455000, China
    Recruiting
    • Mingyong Jia · Contact
  • Jiaozuo Second People's Hospital
    Jiaozuo, Henan 454000, China
    Recruiting
    • Xinqu Xu · Contact
  • Nanyang First People's Hospital
    Nanyang, Henan 473000, China
    Recruiting
    • Qun Ma · Contact
  • Nanyang Second People's Hospital
    Nanyang, Henan 473000, China
    Recruiting
    • Fengling, Ju · Contact
  • Sanmenxia Central Hospital
    Sanmenxia, Henan 472000, China
    Recruiting
    • Kuan Liu · Contact
  • Xinxiang First People's Hospital
    Xinxiang, Henan 453000, China
    Recruiting
    • Xiangjie Zhang · Contact
  • Yichang Central People's Hospital
    Yichang, Hubei 443000, China
    Recruiting
    • Xiaoqi Xiong · Contact
  • Loudi Central Hospital
    Loudi, Hunan 417000, China
    Recruiting
    • Lixuan Chen · Contact
  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia 010030, China
    Recruiting
    • Lihong Wang · Contact
  • The First People's Hospital of Lianyungang City
    Lianyungang, Jiangsu 222061, China
    Recruiting
    • Jiashu Li · Contact
  • Nanjing First Hospital
    Nanjing, Jiangsu 210006, China
    Recruiting
    • Surong Fang · Contact
  • Xuzhou Central Hospital
    Xuzhou, Jiangsu 221009, China
    Recruiting
    • Yanmin Wu · Contact
  • Suining County People's Hospital
    Xuzhou, Jiangsu 221200, China
    Not yet recruiting
  • Yangzhou University Affiliated Hospital
    Yangzhou, Jiangsu 225012, China
    Recruiting
    • Feng Wu · Contact
  • Jiu Jiang NO.1 People's Hospital
    Jiujiang, Jiangxi 332000, China
    Recruiting
    • Jun Li · Contact
  • People's Hospital of Pingxiang City
    Pingxiang, Jiangxi, China
    Recruiting
    • Haibo Shen · Contact
  • The Second Hospital of Jilin University
    Changchun, Jilin 130041, China
    Recruiting
    • Ke Wang · Contact
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
    Recruiting
    • Li Zhao · Contact
  • LiaoCheng People's Hospital
    Liaocheng, Shandong 252000, China
    Recruiting
    • Yan Wang · Contact
  • Qingdao Municipal Hospital
    Qingdao, Shandong 266000, China
    Recruiting
    • Yi Su · Contact
  • The Second People's Hospital of Weifang
    Weifang, Shandong 261041, China
    Recruiting
    • Guoru Yang · Contact
  • Zaozhuang Municipal Hospital
    Zaozhuang, Shandong 277102, China
    Not yet recruiting
  • Zibo Municipal Hospital
    Zibo, Shandong 255499, China
    Recruiting
    • Lijun Suo · Contact
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality 200433, China
    Recruiting
    • Haiwen Lu · Contact
  • The Third People's Hospital of Chengdu City
    Chengdu, Sichuan 610031, China
    Recruiting
    • Guoping Li · Contact
  • The First People's Hospital of Shuangliu District, Chengdu
    Chengdu, Sichuan 610200, China
    Not yet recruiting
  • Chengdu Fifth People's Hospital
    Chengdu, Sichuan 611130, China
    Recruiting
    • Xiao Liu · Contact
  • Mianyang central hospital
    Mianyang, Sichuan 621099, China
    Recruiting
    • Weiguo Xu · Contact
  • Suining Central Hospital
    Suining, Sichuan 629000, China
    Recruiting
    • Rong Qiu · Contact
  • Zigong First People's Hospital Zigong Academy of Medicalsciences
    Zigong, Sichuan 643000, China
    Recruiting
    • Zhiping Deng · Contact
  • The First People's Hospital of Hangzhou (Westlake University Affiliated The First People's Hospital of Hangzhou)
    Hangzhou, Zhejiang 310006, China
    Not yet recruiting
    • wang li ming · Contact
  • The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
    Wenzhou, Zhejiang 325035, China
    Recruiting
    • Liqin Wu · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for May 2028, 26 months after the start.

Of 119 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 26 months is above that.

Counting every sponsor, half of 166 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 11, 2026
StartActual
Mar 6, 2026
Primary completionEst.
May 31, 2028
CompletionEst.
Aug 30, 2028
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07402551
Lead sponsor
Nanjing RegeneCore Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Mar 6, 2026
Primary completion
May 31, 2028 (estimated)
Completion
Aug 30, 2028 (estimated)
Last update
Sep 8, 2026

Study contacts

Yumin Zhou, MD
Contact
zhouyumin410@126.com
+86-13826190798

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RC1416

Start the discussion